SWOG clinical trial number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

15% Accrual
Accrual
15%
Open
Phase
15% Accrual
Accrual
15%
Abbreviated Title
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Status Notes
Active effective 09/19/2022
Activated
09/19/2022
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Genitourinary Cancer

Treatment

Cabozantinib Atezolizumab

Substudy Abstract Page Links

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Reports & Approvals

Trial Locations

Other Clinical Trials

S2312
SWOG Clinical Trial Number
S2210
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
7% Accrual
Accrual
7%
Open
Phase
S2200
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
15% Accrual
Accrual
15%
Open
Phase